ArticleScientific reports2025
Modeling the metastatic tumor microenvironment: a co-culture platform of lung cancer and blood vessel organoids for drug evaluation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Characterization of hepatocellular carcinoma patient-derived organoids from patients receiving transarterial chemoembolization as a model for preclinical drug response assessment.Scientific reports · 2026Article
- Stepwise Differentiation of Mouse Embryonic Stem Cells Into Murine Blood Vessel Organoids With Endothelial Lineage Tracing for Quality Control.Bio-protocol · 2026Article
- A Versatile Microfluidic Extrusion-Based Hydrogel Platform for Self-Organization and Long-Term Maintenance of Engineered 3D Lymphatic Endothelium.Advanced healthcare materials · 2026Article
- Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.Archives of pharmacal research · 2026Review
- Organoid-Derived Extracellular Vesicles: From Biogenesis and Cargo Mechanisms Toward Therapeutic Applications.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cell-vasculature interactions play a crucial role in lung cancer progression and metastasis; however, traditional cell culture models rarely capture these complex dynamics. We developed a vascularized lung cancer organoid (VLCO) model by coculturing lung cancer organoids (LCOs) with blood vessel organoids (BVOs) to recreate the tumor-vasculature niche in a three-dimensional in vitro system. During coculture, LCOs migrated along BVO-formed vascular networks and invaded vessel-like structures, mimicking intravasation. The organoid types interacted via secretory factors, including TGF-β and PDGF-BB, inducing epithelial-mesenchymal transition (EMT) in LCOs and pericyte-to-fibroblast transition in BVOs. We also developed a scalable drug response assay for vasculature-induced EMT, enabling targeted therapeutic screening. The VLCO model provides a robust platform for studying tumor-endothelial crosstalk and testing antimetastatic therapies targeting tumor-vasculature interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.